Search - tctmd.com

Displaying 41 - 60 of 108

Sort: Relevancy | Date

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

News Daily News

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

July 24, 2018

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

News Daily News

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

July 11, 2018

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

July 10, 2018

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

July 06, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

News Daily News

NAVIGATE ESUS: Rivaroxaban Fails to Prevent More Recurrent Cryptogenic Strokes Than Aspirin

May 16, 2018

NOACs Perform Worse Than Warfarin in Real-World Study, Especially When Adherence Is Low

News Conference News HRS 2018

NOACs Perform Worse Than Warfarin in Real-World Study, Especially When Adherence Is Low

May 11, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Research Series Sheds Light on Questions Surrounding Stroke Risk in Women

News Daily News

Research Series Sheds Light on Questions Surrounding Stroke Risk in Women

February 09, 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

News Conference News ISC 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

January 30, 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

News Conference News ISC 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

January 27, 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

January 25, 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

January 02, 2018

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

December 04, 2017

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

November 22, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.